Dimensional Fund Advisors LP Has $98.91 Million Stock Position in Bruker Co. (NASDAQ:BRKR)

Dimensional Fund Advisors LP grew its holdings in Bruker Co. (NASDAQ:BRKR - Free Report) by 22.8% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 1,687,364 shares of the medical research company's stock after acquiring an additional 313,171 shares during the period. Dimensional Fund Advisors LP owned 1.11% of Bruker worth $98,914,000 as of its most recent SEC filing.

Several other large investors also recently made changes to their positions in BRKR. FIL Ltd grew its position in Bruker by 262.3% during the fourth quarter. FIL Ltd now owns 1,961,416 shares of the medical research company's stock worth $114,978,000 after buying an additional 1,420,102 shares in the last quarter. Norges Bank bought a new stake in shares of Bruker in the 4th quarter worth about $63,378,000. Marshall Wace LLP increased its holdings in shares of Bruker by 4,510.3% during the fourth quarter. Marshall Wace LLP now owns 783,988 shares of the medical research company's stock worth $45,957,000 after buying an additional 766,983 shares in the last quarter. Vaughan Nelson Investment Management L.P. boosted its stake in Bruker by 140.3% in the fourth quarter. Vaughan Nelson Investment Management L.P. now owns 1,141,762 shares of the medical research company's stock worth $66,930,000 after purchasing an additional 666,617 shares in the last quarter. Finally, JPMorgan Chase & Co. lifted its position in Bruker by 139.3% during the 4th quarter. JPMorgan Chase & Co. now owns 526,166 shares of the medical research company's stock worth $30,844,000 after buying an additional 306,282 shares in the last quarter. Institutional investors own 79.52% of the company's stock.

Bruker Price Performance

BRKR traded up $0.97 during trading on Friday, hitting $40.32. 1,283,677 shares of the stock traded hands, compared to its average volume of 1,526,758. The company has a debt-to-equity ratio of 1.15, a current ratio of 1.60 and a quick ratio of 0.77. Bruker Co. has a twelve month low of $34.10 and a twelve month high of $79.78. The company has a market cap of $6.11 billion, a price-to-earnings ratio of 52.95, a PEG ratio of 2.16 and a beta of 1.18. The business has a 50 day moving average price of $42.26 and a 200 day moving average price of $52.11.

Bruker (NASDAQ:BRKR - Get Free Report) last issued its quarterly earnings data on Thursday, February 13th. The medical research company reported $0.76 EPS for the quarter, beating the consensus estimate of $0.75 by $0.01. Bruker had a net margin of 3.36% and a return on equity of 21.01%. Equities research analysts forecast that Bruker Co. will post 2.69 earnings per share for the current fiscal year.

Bruker Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Friday, March 28th. Investors of record on Monday, March 17th were paid a $0.05 dividend. The ex-dividend date was Monday, March 17th. This represents a $0.20 annualized dividend and a dividend yield of 0.50%. Bruker's dividend payout ratio is 26.32%.

Analysts Set New Price Targets

Several equities research analysts have recently commented on the company. Barclays lowered their target price on Bruker from $60.00 to $50.00 and set an "overweight" rating for the company in a research note on Thursday, April 10th. Citigroup cut their price target on shares of Bruker from $75.00 to $50.00 and set a "buy" rating on the stock in a research report on Monday, April 7th. Wells Fargo & Company cut their price target on shares of Bruker from $75.00 to $60.00 and set an "overweight" rating for the company in a research note on Thursday, April 17th. Guggenheim reiterated a "buy" rating on shares of Bruker in a research note on Monday, February 24th. Finally, Stifel Nicolaus lowered their price target on shares of Bruker from $70.00 to $57.00 and set a "hold" rating on the stock in a report on Friday, February 14th. Six analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. According to MarketBeat.com, Bruker presently has an average rating of "Moderate Buy" and an average target price of $65.00.

About Bruker

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.